Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8062807 | 1.00 | GPR119 (0.34) | GPR119DPP4ABCB1SCN9ACETP | |
| SCHEMBL13040213 | 1.00 | GPR119 (0.34) | GPR119DPP4ABCB1SCN9ACETP | |
| SCHEMBL3405050 | 0.89 | GPR119 (0.34) | GPR119DPP4ABCB1SCN9ACETP | |
| SCHEMBL3407576 | 0.89 | GPR119 (0.34) | GPR119DPP4ABCB1SCN9ACETP | |
| SCHEMBL13040214 | 0.89 | GPR119 (0.34) | GPR119DPP4ABCB1SCN9ACETP | |
| SCHEMBL3408723 | 0.85 | — | — | |
| SCHEMBL3403073 | 0.85 | — | — | |
| SCHEMBL3717928 | 0.78 | DPP4 (0.39) | GPR119DPP4ABCB1SCN9ACETP | |
| SCHEMBL2348001 | 0.75 | DPP4 (0.40) | GPR119DPP4ABCB1CETP | |
| SCHEMBL2348006 | 0.75 | DPP4 (0.40) | GPR119DPP4ABCB1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| WO-2009081959-A1 | PROCESS FOR PRODUCTION OF 4-(SUBSTITUTED PHENYL)HEXAHYDROPYRIDO[2,1-C][1,4]OXAZIN-6-ONE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | PSEN1, APP, BACE1 | GPR119 3142/4885DPP4 166/4885ABCB1 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.